Mazindol ER in Narcolepsy, Zürich Videos

Videos by Mazindol ER in Narcolepsy in Zürich. The POLARIS clinical development program is being conducted by NLS Pharmaceutics.

NLS Pharmaceutics at World Sleep 2022

NLS Pharmaceutics is presenting interim top-line data on the phase 2a study in narcoleptic patients at the World Sleep Congress in Rome today March 16, 2022, 12:30pm - 2:00pm (CET).

#worldsleep2022 #narcolepsy #worldsleepsociety #forbetterhealth #cns #cataplexy #narcolepsyawareness

Click

to enable sound Next

Go to Mazindol ER in Narcolepsy main page

Other Mazindol ER in Narcolepsy videos

NLS Pharmaceutics at World Sleep 2022
NLS Pharmaceutics is presenting interim top-line data on the phase 2a study in narcoleptic patients at the World Sleep Congress in Rome today March 16, 2022, 12:30pm - 2:00pm (CET). #worldsleep2022 #narcolepsy #worldsleepsociety #forbetterhealth #cns #cataplexy #narcolepsyawareness

How does mazindol work?
Mazindol has a dual action: • It acts as a partial Orexin 2 Receptor Agonist that may help replace the missing #orexin (endogenous orexin peptide), addressing the underlying cause of #narcolepsy; • It also acts as a reuptake inhibitor of #dopamine, #norepinephrine, and #serotonin, that can further reduce disease specific symptoms. A proprietary extended-release formulation of mazindol (mazindol ER) is being evaluated by NLS Pharmaceutics in the POLARIS Clinical Development Program in adult subjects suffering from narcolepsy.